RxDoctor Payments Data

Harry Holliday, MD

Pulmonary Disease · Starkville, MSNPI 1053335372

Payments from drug & device makers

$1,888in general payments, 2019–2025

Across 109 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$352
  • Mylan Specialty L.p.$338
  • Inspire Medical Systems, Inc.$242
  • Harmony Biosciences LLC$158
  • AstraZeneca$115
  • Electromed, Inc.$80
  • plus $602 from 18 others

What the payments were for

  • Food & beverage$1,87299%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,888 in reported general payments places this provider in the 30th percentile of 101 pulmonary disease providers in Mississippi.

See all pulmonary disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$126,027
Medicare patients
840
Services billed
2,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor13$189,430
Trelegy ElliptaFluticasone/Umeclidin/Vilanter223$187,365
Breztri AerosphereBudesonide/Glycopyr/Formoterol107$81,464
Breo ElliptaFluticasone/Vilanterol112$60,094
Dupixent SyringeDupilumab13$57,382
Spiriva RespimatTiotropium Bromide47$31,032
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$16,535
SymbicortBudesonide/Formoterol Fumarate51$15,919
Bosentan12$13,958
Combivent RespimatIpratropium/Albuterol Sulfate12$13,920
Albuterol Sulfate HfaAlbuterol Sulfate318$10,628
Incruse ElliptaUmeclidinium Bromide21$6,986
Advair HfaFluticasone Propion/Salmeterol17$6,551
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate33$5,433
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$5,095

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$352$259,475383 claims
Grifols USA, LLCProlastin C$73$189,43013 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler$115$107,164192 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$56$61,48792 claims
MerckDulera$28$4,79216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 101 pulmonary disease providers in Mississippi.

Other pulmonary disease in Starkville

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →